Author Archives: donttradeourlivesaway

Data exclusivity back on the table for India

Source : Spicy IP, March 27, 2015 D.G. Shah, Secretary General of the Indian Pharmaceutical Alliance sends us news that will be of interest to many of our readers. He says, “… Government plans to introduce a Pesticides (Amendment) Bill … Continue reading

Posted in data exclusivity, TRIPS plus | Leave a comment

12 cancer drugs may come under price control

Source : Indian Express, May 5, 2015 As per the pharmaceutical pricing policy passed in 2012, any brand of drugs included in NLEM cannot cost more than the weighted average of all brands of that particular medicine that have a … Continue reading

Posted in Drug Pricing | Leave a comment

Mixed signals not a good sign for IPR

Source : Business Today, April 29, 2015 On April 23, while speaking at a three-day Global Exhibition of Services in New Delhi, Prime Minister Narendra Modi made a statement that intrigued many in the Indian pharmaceutical industry. Though he spoke … Continue reading

Posted in Indian Patent Law, Make in India Campaign, Sec 3 (d), TRIPS, US pressure on India | Leave a comment

How Marketing Exclusivity Led to Higher Drug Costs and Questionable Benefits

Source- Wall Street Journal Pharmalot, 6 May, 2015 Six years ago, the FDA approved a drug called Colcrys to treat acute gout attacks and familial Mediterranean fever, an inherited inflammatory disorder. The move came as part of an agency initiative … Continue reading

Posted in data exclusivity, TRIPS plus | Leave a comment

India again on US IPR priority watch list; Govt disappointed, but not worried

Source : The Hindu, 1 May, 2015 India is disappointed at being featured yet again in the US Priority Watch List of weak IPR countries. But it is not worried. A senior Commerce & Industry Ministry official told BusinessLine that … Continue reading

Posted in Indian Patent Law, Intellectual Property, TRIPS, TRIPS plus, US pressure on India, USTR 301 report | Leave a comment

In Search of ‘Just’ Prices: Questioning the High Cost of New Cancer Drugs – A Conversation With Hagop M. Kantarjian, MD

Source : The ASCO Post, 25 April, 2015 As the oncology community begins the slow and often difficult-to-define transition from volume to value in the delivery of cancer care, the relationship between the price and value of certain high-priced cancer … Continue reading

Posted in access to medicines, Cancer | Leave a comment

India remains on USTR priority watch list

Source : Express Pharma, 4 May, 2015 But no OCR this year … as yet India remains on the US Trade Representative’s Priority Watch list of its annual Special 301 review. Unlike last year, the USTR is not announcing an … Continue reading

Posted in Indian Patent Law, Intellectual Property, Out of Cycle Review (OCR), TRIPS, TRIPS plus, US pressure on India, USTR 301 report | Leave a comment